Rare Disease

What are the keys to making rare disease drug development sustainable?

Pharma's Almanac

PFDD

How are companies meaningfully incorporating patient voices into drug development decisions?

Pharma's Almanac

In VIvo CAR-T

In Vivo CAR-T Technology Poised to Expand Access and Indications

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Pediatric Cancer

Bridging the Gap in Pediatric Cancer Access...A Call to Investors and Pharma Leaders

Emilee Kudla; David Alvaro, Ph.D.

Pharma's Almanac

Women in Science

What progress has the industry made in advancing women in leadership, R&D, and clinical roles?

Pharma's Almanac

Rare Disease Equity

Advancing Equity in Rare Disease Trials: Global Realities, Local Solutions

Rose Blackburne, M.D., MBA; Radojica Savic, M.D.; Galina Nesterova, MD

PPD clinical research business of Thermo Fisher Scientific

Health Equity

How is the pharmaceutical industry addressing global health inequities?

Pharma's Almanac

Global Access

How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications?

Pharma's Almanac

Customer Centricity

What to Look for When Choosing the Right CDMO

Michael Kays; Jeremy Tatum

TriRx Pharmaceutical Services